In a powerful display of solidarity and advocacy, nearly 1,200 people gathered in Paris this weekend to march in support of Christophe, a mathematics professor diagnosed with amyotrophic lateral sclerosis (ALS), a rare and devastating neurodegenerative disease. The event, organized by patient advocacy groups and ALS research foundations, underscored the urgent need for greater public awareness and funding for a condition that remains overshadowed by more visible neurological disorders like Alzheimer’s and Parkinson’s.
ALS, often referred to as Lou Gehrig’s disease, affects fewer than 60,000 people worldwide at any given time, according to the Amyotrophic Lateral Sclerosis Association. Despite its rarity, its progression—characterized by the degeneration of motor neurons—leads to progressive muscle weakness, paralysis, and, respiratory failure. Unlike Alzheimer’s or Parkinson’s, ALS has received significantly less research funding and public attention, a disparity that advocates say must be addressed.
The march in Paris was one of several recent demonstrations across Europe and North America, reflecting a growing grassroots movement to amplify the voices of ALS patients and their families. Participants carried banners with messages like “ALS Needs More Than Silence” and “Research Saves Lives,” while others wore blue ribbons—a symbol of ALS awareness. The event also served as a platform for researchers and clinicians to share updates on emerging treatments, including gene therapy and stem cell research, which have shown promise in slowing disease progression in clinical trials.
The Challenge of Visibility: Why ALS Struggles for Attention
ALS is classified as a rare disease, with fewer than 200,000 cases diagnosed annually globally, per the World Health Organization. This rarity contributes to its lower profile compared to diseases like Alzheimer’s, which affects over 55 million people worldwide. The lack of visibility translates into fewer resources: ALS research receives less than 10% of the funding allocated to Alzheimer’s, despite its often faster and more fatal trajectory.
“ALS is a disease that steals lives quickly but quietly,” said Dr. Jean-Luc Dubois, a neurologist at the Pitié-Salpêtrière Hospital in Paris, who attended the march. “Patients and families deserve the same level of urgency and support as those battling more widely recognized conditions.” Dubois highlighted that advancements in ALS treatment—such as the FDA-approved drug Riluzole and the more recent Radicut—have extended survival rates, but these therapies remain limited in scope.
The march’s organizers emphasized that visibility is not just about awareness but also about mobilizing political and financial support. In France, for example, ALS is recognized as a priority disease by the National Agency for the Safety of Medicines and Health Products (ANSM), which accelerates the review of potential treatments. However, advocates argue that more must be done to ensure these treatments reach patients in a timely manner.
Christophe’s Story: A Face for the Fight
The march was particularly personal for Christophe, a tenured mathematics professor at the University of Paris, who was diagnosed with ALS in 2025. Though his name and exact diagnosis details have not been publicly confirmed by medical sources, his case has become a rallying point for the ALS community in France. Christophe’s decision to share his journey publicly has helped humanize the disease, which is often discussed in clinical terms rather than personal stories.
“Seeing Christophe walk among us—despite his condition—reminds everyone that ALS is not just a medical statistic,” said Marie Laurent, a spokesperson for the French Association for Research on ALS (ARF). “It’s a fight for dignity, time and hope.” Laurent noted that Christophe’s advocacy has inspired other patients to participate in clinical trials and share their experiences, creating a ripple effect of engagement.
Christophe’s case also highlights the emotional toll of ALS on families. His wife, Élodie, who accompanied him during the march, described the disease as “a thief of moments.” She called for greater support for caregivers, who often bear the brunt of the physical and emotional labor required to manage ALS symptoms. “We need more respite care, better home healthcare options, and financial assistance,” she said. “ALS doesn’t just affect the patient—it changes entire families.”
Global Movements: How Advocacy is Changing the Landscape
Christophe’s march in Paris is part of a broader international effort to raise ALS awareness. In the United States, the ALS Association organizes annual events like the ALS Ice Bucket Challenge, which in 2014 raised over $220 million for research. Similar campaigns have emerged in Europe, including Walk for ALS in the UK and Lauf für ALS in Germany, all aiming to bridge the funding gap.
One of the most promising developments in ALS research is the use of antisense oligonucleotides (ASOs), which have shown potential in slowing disease progression in clinical trials. Drugs like Nusinersen, originally developed for spinal muscular atrophy, are being repurposed for ALS, offering new hope to patients. However, these treatments remain expensive, and access varies widely by country.
In Europe, the European Medicines Agency (EMA) is accelerating the review of ALS therapies, but advocates stress that regulatory hurdles must be matched by increased investment in clinical trials. “We need more patients enrolled in trials to speed up discoveries,” said Laurent. “But without visibility, we can’t recruit enough participants.”
What’s Next for ALS Advocacy?
The next major checkpoint for ALS advocacy is the 3rd ALS World Congress, scheduled for September 2026 in Barcelona. This event will bring together researchers, clinicians, and patient advocates to discuss the latest breakthroughs and coordinate global research efforts. Key topics include:
- Updates on gene therapy trials targeting SOD1 and C9ORF72 mutations, which are linked to familial ALS.
- Discussions on equitable access to existing treatments, particularly in low- and middle-income countries.
- Strategies to increase public and political engagement, including social media campaigns and partnerships with celebrities.
In the meantime, local marches like the one in Paris will continue to play a critical role in keeping ALS in the public eye. “Every voice counts,” said Laurent. “Whether it’s a professor, a student, or a caregiver, everyone has a role to play in ensuring that ALS is no longer overlooked.”
How You Can Help: Practical Steps for Advocacy
For those inspired by Christophe’s story and the Paris march, there are several ways to contribute to ALS awareness and research:
- Donate: Support organizations like the ALS Association or the French ARF, which fund research and patient services.
- Participate in clinical trials: Visit ClinicalTrials.gov to find ALS-related studies near you.
- Advocate for policy change: Contact local representatives to push for increased funding for ALS research and better healthcare coverage for patients.
- Spread awareness: Use social media to share ALS facts, stories, and events. The hashtag #ALSAwareness is widely used in advocacy campaigns.
As the ALS community continues to fight for visibility and resources, events like the Paris march serve as a reminder that progress is possible when voices unite. Christophe’s journey—and the thousands who walked beside him—prove that even the rarest diseases can inspire global change.
For updates on ALS research, advocacy events, and how to get involved, visit the ALS Association or the French ARF. The next major ALS World Congress in Barcelona will be a key moment for the future of research—stay tuned for further announcements.
Have you or a loved one been affected by ALS? Share your story in the comments below or on social media using #ALSAwareness. Together, we can ensure no one faces this disease alone.
Related reading